While RSV is widely recognized as a severe threat to infants, the virus also drives significant hospitalizations among older adults and individuals with chronic respiratory conditions. Hospital data spanning a three-year period revealed a cumulative 1,093 inpatient days for these cohorts, including 91 days spent in the intensive care unit.
Antibody Titers Decline During Second Respiratory Season
- Duration of Protection: Clinical observations indicate that vaccine-induced humoral immunity persists across two to three consecutive respiratory seasons, though antibody titers demonstrate a measurable decline in the second season.
Health Council Recommends Vaccination for Older Adults
The Health Council of the Netherlands (Gezondheidsraad) issued an advisory in March 2025 recommending RSV vaccination for all individuals aged 75 and older, alongside targeted risk groups and nursing home residents aged 60 to 75. However, a comprehensive national immunization program has stalled as public health authorities await definitive longitudinal data regarding the exact duration of clinical protection. The Health Care Institute (Zorginstituut) previously advised against reimbursing the Arexvy vaccine, concluding that its added value for broader risk categories remained insufficiently proven at the time.
In Germany, health authorities authorized vaccine reimbursement for residents aged 75 and older as well as vulnerable adults aged 60 and older beginning in late 2024. In the United Kingdom, the National Health Service (NHS) provides the immunization free of charge to individuals turning 75 and to older adults residing in care homes. Meanwhile, the Dutch infant population gained access to an RSV immunization via the National Immunization Program in the autumn of 2025, contributing to a drop in pediatric intensive care admissions from 222 infants down to 87 during the subsequent season.
| Metric / Patient Group | Immunocompetent Adults (60+) | Compromised Immune Defenses |
|---|---|---|
| Ikazia Hospital Admission Drop (2025 vs. Current) | 95 admissions | 34 admissions |
| Estimated Vaccine Acquisition Cost | ~€200 per dose | ~€200 per dose |
High Vaccine Efficacy Averts Hospital Admissions
Dr. Kroesse noted that while a single vaccine dose costs approximately 200 euros, an acute hospital admission easily scales into thousands of euros. Susanne Huijts of the infectious diseases section of the Netherlands Association of Physicians for Pulmonary Diseases and Tuberculosis (NVALT) emphasized the high efficacy of current formulations, pointing to independent sampling data indicating that over 80 percent of targeted hospitalizations can be averted. The RIVM estimates that approximately 3,000 individuals aged 65 and older are admitted to hospitals with RSV annually, though actual incidence figures are likely higher due to under-testing.
Upcoming Regulatory Evaluations and the 2027 Outlook
The Health Care Institute is actively evaluating three distinct RSV vaccine candidates specifically intended for medical risk groups, with a formal advisory scheduled for release in early 2027. Following that evaluation, the Dutch Minister of Health, Welfare and Sport (VWS) will decide whether to integrate the inoculations into national reimbursement frameworks. In the interim, adults seeking immunization outside of institutional pilot programs must cover the acquisition costs independently, while national surveillance data from the RIVM reported on November 4 that current baseline circulation of the virus remains low as the winter respiratory season begins.
References
- Gezondheidsraad (Health Council of the Netherlands) – Advisory on RSV Vaccination for Older Adults and Risk Groups (March 2025).
- Zorginstituut Nederland – Vaccine Assessment and Reimbursement Evaluations.
